Advertisement

A Population-Based Cohort Study Examining the Long-term Risk of Repeated Surgery in Non-Helicobacter pylori-Infected PPU Patients Who Underwent Simple Closure

  • Shih-Chi WuEmail author
  • William Tzu-Liang Chen
  • Chih-Hsin Muo
  • Chung Y. Hsu
Original Article
  • 26 Downloads

Abstract

Objectives

The management of perforated peptic ulcer (PPU) has shifted from vagotomy/drainage to simple closure, followed by postoperative proton pump inhibitors (PPIs) and Helicobacter pylori (HP) eradication. Few studies have focused on the long-term impacts of this trend shift. We hypothesize that simple closure with PPIs is sufficient and does not carry an elevated rate of repeated surgery in non-HP-infected PPU patients.

Methods

Hospitalized PPU patients who underwent simple closure or truncal vagotomy/pyloroplasty (TVP) in the National Health Insurance Research Database (NHIRD) from 2000 to 2008 were collected. The index date was defined as the date of ulcer admission. Patients who underwent other ulcer surgeries (e.g., gastrectomy, highly or selective vagotomy), who had a history of HP infection, or who were < 18 or > 100 years old were excluded. Additionally, the distributions of postoperative nonsteroidal anti-inflammatory drug (NSAID) and PPI use were calculated using the Longitudinal Health Insurance Database (LHID).

Results

After exclusion, a total of 66,413 patients were enrolled. There were 7232 (10.9%) patients who underwent TVP and 59,181 (89.1%) patients who underwent simple closure. The incidences of repeated ulcer-associated surgery were 5.10 and 23.05 versus 5.11 and 15.77 per 1000 person-years in the TVP cohort vs. the simple closure cohort before and after propensity score matching, respectively. When adjusted for age, sex, comorbidity, and Charlson comorbidity index score, the TVP cohort had a 68% (HR) and 66% (sHR) decreased risk compared with the simple closure cohort before propensity score matching, with a 67% decreased risk after propensity score matching in Cox proportional subdistribution hazard analysis and a 66% decreased risk in Fine-Gray proportional subdistribution hazard analysis. The LHID analysis showed a lower rate of postoperative NSAID use and a higher rate of postoperative PPI use in simple closure patients.

Conclusion

Our findings suggest that in the Asian population, simple closure increases the risk of repeated ulcer-associated surgery in non-HP-infected PPU patients compared with TVP patients. However, further studies are warranted.

Keywords

Perforated peptic ulcer Simple closure Vagotomy Recurrent perforation 

Abbreviations

PPU

perforated peptic ulcer

PPI

proton pump inhibitors (PPIs)

HP

helicobacter pylori

TVP

truncal vagotomy/pyloroplasty

NHIRD

National Health Insurance Research Databases

NSAIDs

nonsteroidal anti-inflmmatory drugs

LHID

Longitudinal Health Insurance Database

CCI

Charlson comorbidity index

GERD

gastroesophageal reflux disease

ICD-9-CM

International Classification of Diseases, Ninth Revision, Clinical Modification

AIDS

acquired immune deficiency syndrome

Cls

confidence intervals

HR

hazard ratio

SHR

subdistribution hazard ratio

BMI

body mass index

Notes

Author Contributions

Wu SC conceived and designed the study and wrote the initial draft of the manuscript; Chen WT participated in study design and conception; Muo CH performed the data analysis and interpretation and was involved in writing the initial draft of manuscript; Wu SC and Hsu CY performed data analysis and interpretation as well as manuscript drafting and revision. Guarantor of the article: Shih-Chi Wu, MD, PhD.

Funding Information

This study is supported in part by the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University Hospital (DMR-107-192), Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Ethics Approval and Consent to Participate

For complying with the Personal Information Protection Act, the data abstracted from the chart contained no identification of patient information. All identifications of patients were replaced with surrogate numbers for research uses. This study was approved by the Research Ethics Committee at China Medical University and Hospital (CMUH106-REC3-085).

Supplementary material

11605_2019_4442_MOESM1_ESM.docx (26 kb)
ESM 1 (DOCX 25 kb)

References

  1. 1.
    Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009 May 1; 29(9):938-46.PubMedCrossRefGoogle Scholar
  2. 2.
    Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 80e9.CrossRefGoogle Scholar
  3. 3.
  4. 4.
    Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician. 2007; 76:1005-12.PubMedGoogle Scholar
  5. 5.
    University of Michigan Health System. Peptic ulcer disease. Accessed May 4, 2007, at: http://www.cme.med.umich.edu/pdf/guideline/PUD05.pdf.
  6. 6.
    Liang C-C, Muo C-H, Wang I-K, et al. (2014) Peptic Ulcer Disease Risk in Chronic Kidney Disease: Ten-Year Incidence, Ulcer Location, and Ulcerogenic Effect of Medications. PLoS ONE 9(2): e87952PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009 Oct 24; 374(9699):1449-61.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Connor A, Gisbert JP, O'Morain C, et al. Treatment of Helicobacter pylori Infection 2015. Helicobacter. 2015; 20 Suppl 1:54-61.PubMedCrossRefGoogle Scholar
  9. 9.
    Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002; 162:153-60.PubMedCrossRefGoogle Scholar
  10. 10.
    Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995; 9 Suppl 2:59-69.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014; 20(36):12781–12808.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Bertleff MJ, Lange JF. Perforated peptic ulcer disease: a review of history and treatment. Dig Surg. 2010; 27:161–169.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011; 84:102–113.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Lagoo J, Pappas TN, Perez A. A relic or still relevant: the narrowing role for vagotomy in the treatment of peptic ulcer disease. Am J Surg. 2014; 207:120-6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Miwa H, Sakaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter. 2004 Feb; 9(1):9-16.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg. 2000; 231:153-158.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Nyhus LM, Baker RJ, Fischer JE. Mastery of surgery. 3rd ed. Boston:Little, Brown; 1997.Google Scholar
  18. 18.
    Søreide K, Thorsen K, Harrison EM, et al. Perforated peptic ulcer. Lancet. 2015; 386(10000):1288-98.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Wong CS, Chia CF, Lee HC, et al. Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. J Surg Res 2013; 182: 219–26.PubMedCrossRefGoogle Scholar
  20. 20.
    Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947–53.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Ngamruengphong S, Leontiadis G, Radhi S, Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011 Jul;106(7):1209-18PubMedCrossRefGoogle Scholar
  22. 22.
    Lin SM, Yang SH, Liang CC, et al. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018 Jan; 29(1):153-162.PubMedCrossRefGoogle Scholar
  23. 23.
    Peng YC, Huang LR, Lin CL, et al. Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut. 2018 Feb 22. pii: gutjnl-2018-316057.  https://doi.org/10.1136/gutjnl-2018-316057 PubMedCrossRefGoogle Scholar
  24. 24.
    Chien LN, Huang YJ, Shao YH, et al. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study. Int J Cancer. 2016 Mar 15; 138(6):1401-9.PubMedCrossRefGoogle Scholar
  25. 25.
    Parsons LS. Performing a 1: N case-control match on propensity score. In: Proceedings of the 29th Annual SAS Users Group International Conference; May 9-12, 2004; Montreal, CanadaGoogle Scholar
  26. 26.
    Hu WS, Lin CL. Risk of Atrial Fibrillation in Patients with Congenital Heart Disease: Results of a Propensity Score-Matched, Nationwide Cohort Study. J Atheroscler Thromb. 2019 Jul 1;26(7):670-677.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Chronic Dis. 1987; 40(5):373-83.CrossRefGoogle Scholar
  28. 28.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun; 45(6):613-9.CrossRefGoogle Scholar
  29. 29.
    Nada T, Nomura M, Iga A,et al. Autonomic nervous function in patients with peptic ulcer studied by spectral analysis of heart rate variability. J Med. 2001; 32(5-6):333-47.PubMedGoogle Scholar
  30. 30.
    Yukinaka M, Nomura M, Saijyo T, et al. Evaluation of autonomic nervous function in patients with essential hypertension complicated with peptic ulcer. J Gastroenterol Hepatol. 2000; 15:40-4.PubMedCrossRefGoogle Scholar
  31. 31.
    Cho CH, Qui BS, Bruce IC. Vagal hyperactivity in stress induced gastric ulceration in rats. J Gastroenterol Hepatol. 1996; 11:125-8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Wu SC, Chen WT, Fang CW, et al. Association of vagus nerve severance and decreased risk of subsequent type 2 diabetes in peptic ulcer patients: An Asian population cohort study. Medicine (Baltimore). 2016 Dec; 95(49):e5489.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Wu SC, Fang CW, Chen WT, et al. Acid-reducing vagotomy is associated with reduced risk of subsequent ischemic heart disease in perforated peptic ulcer: An Asian population study. Medicine (Baltimore). 2016 Dec; 95(50):e5651.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Fang CW, Tseng CH, Wu SC, et al. Association of Vagotomy and Decreased Risk of Subsequent Ischemic Stroke in Perforated peptic ulcer Patients: an Asian Population Study. World J Surg. 2017 Dec;41(12):3171-3179PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Cheng TJ, Guo HR, Chang CY, et al. The Association Between Peptic Ulcer Disease and Ischemic Stroke: A Population-Based Longitudinal Study. Medicine (Baltimore). 2016 May; 95(22):e3797.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Arai I, Hirose H, Muramatsu M, et al. Possible involvement of non-steroidal anti-inflammatory drugs in vagal-mediated gastric acid secretion in rats. Jpn J Pharmacol. 1985 Jan; 37(1):91-9.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Mulholland MW, Doherty G. Complications in surgery. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.CrossRefGoogle Scholar
  38. 38.
    Adami HO, Enander LK, Enskog L, et al. Recurrences 1 to 10 years after highly selective vagotomy in prepyloric and duodenal ulcer disease. Frequency, pattern, and predictors. Ann Surg 1984; 199:393–9.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health. 2009;6(1):209–224. doi: https://doi.org/10.3390/ijerph6010209 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014 Jan; 23(1):43-50.PubMedCrossRefGoogle Scholar
  41. 41.
    Musumba C, Jorgensen A, Sutton L, et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther. 2012 Jul; 36(1):48-56.PubMedCrossRefGoogle Scholar
  42. 42.
    Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol. 2010 Jun 20; 28(18):2952-7.PubMedCrossRefGoogle Scholar
  43. 43.
    Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. Ambulatory Setting, 2002–2009. PLoS One 2013; 8:e56060.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun 2008; 76:639–45.PubMedCrossRefGoogle Scholar
  45. 45.
    Graham DY, Genta RM. Long term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008; 10:543–7.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Ohnishi S, Ma N, Thanan R, et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Long 2013; 2013:387014.Google Scholar
  47. 47.
    Schroder VT, Pappas TN, Vaslef SN, et al. Vagotomy/drainage is superior to local oversew in patients who require emergency surgery for bleeding peptic ulcers. Ann Surg. 2014 ;259(6):1111-8PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  1. 1.Graduate Institute of Clinical Medical ScienceChina Medical UniversityTaichungTaiwan
  2. 2.Trauma and Emergency CenterChina Medical University HospitalTaichungRepublic of China
  3. 3.Department of SurgeryChina Medical University HospitalTaichungTaiwan
  4. 4.Management Office for Health DataChina Medical University and HospitalTaichungTaiwan

Personalised recommendations